Zydus Lifesciences subsidiary Sentynl Therapeutics has announced the worldwide acquisition of the Zokinvy (lonafarnib) programme from Eiger BioPharmaceuticals for the treatment of progeria.
SOLANA BEACH, Calif. and AHMEDABAD, India and PALO ALTO, Calif., May 3, 2024 /PRNewswire/ -- Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group), and Eiger BioPharmaceuticals, Inc. (OTC: EIGRQ), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced the closing of the sale of Eiger's Zokinvy® (lonafarnib) program to Sentynl.
Sentynl Therapeutics, Inc, a US-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group), has announced The Medicines and Healthcare products Regulatory Agency (MHRA) authorization of Nulibry (fosdenopterin) for injection as the first therapy for the treatment of patients in Great Britain with molybdenum cofactor deficiency (MoCD) type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants. MoCD type A is known to impact fewer than 150 patients globally with a median survival age of four years.